minimal change disease; Membranous nephropathy; nephrotic-range proteinuria; Based on the current case data, this case has been classified as invalid. This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MINIMAL LESION (minimal change disease) and GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.       No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced GLOMERULONEPHRITIS MINIMAL LESION (minimal change disease) (seriousness criterion medically significant), GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) (seriousness criterion medically significant) and PROTEINURIA (nephrotic-range proteinuria). At the time of the report, GLOMERULONEPHRITIS MINIMAL LESION (minimal change disease), GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) and PROTEINURIA (nephrotic-range proteinuria) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered GLOMERULONEPHRITIS MINIMAL LESION (minimal change disease), GLOMERULONEPHRITIS MEMBRANOUS (Membranous nephropathy) and PROTEINURIA (nephrotic-range proteinuria) to be possibly related.    Treatment for the events was not reported.  Concomitant medications were not reported.  Presenting with nephrotic-range proteinuria 1-3 weeks after COVID-19 vaccine In all patients, sCr was 0.5-1.2 mg/dl and UPCR 4.5-7.6 g/g. 1 patient had MCD in remission diagnosed 6 months prior; others had no relevant PMH. All workup was negative, except low positive ANA in 2 patients. On KBx, diagnosis of MCD was made in 4 and stage I membranous nephropathy (MN) in 1 patient(s) (serum albumin 2.0-2.4g/dl in MCD and 3.6g/dl in MN patient(s)); all had mild chronic changes. All 4 MCD patients had fine granular punctate podocyte staining for polyclonal IgG colocalizing with nephrin by IF and diffuse FPE by EM; in 1 patient plasma was saved during NS and was serologically positive for anti-nephrin. The MN patient had 3+ fine granular IF staining for polyclonal IgG and PLA2r along GBMs with sparse superficial subepithelial electron-dense deposits on EM, and was serologically negative for antinephrin. All MCD patients were successfully treated with oral glucocorticoids, while the MN patient was monitored closely under RAAS blockage.  This Literature-Non-Study case concerns a patient of unknown age and gender, with no relevant medical history, who experienced the serious unexpected events of Glomerulonephritis minimal lesion and Glomerulonephritis membranous. The events occurred after the mRNA-1273 vaccine, dose number not provided. The rechallenge was not applicable since dose number was not provided. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   This case was linked to MOD-2021-380900 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 11-Nov-2021: Follow up received by safety 11-Nov-2021 included an Email received from RA team and contains new information. Lab details were updated. Added authors names and event PROTEINURIA from initial document.; Sender's Comments: This Literature-Non-Study case concerns a patient of unknown age and gender, with no relevant medical history, who experienced the serious unexpected events of Glomerulonephritis minimal lesion and Glomerulonephritis membranous. The events occurred after the mRNA-1273 vaccine, dose number not provided. The rechallenge was not applicable since dose number was not provided. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.